Form 4: Altimmune Director Acquires Stock Options

Altimmune director Jerome Benedict Durso acquired 69,800 stock options on February 24, 2025, exercisable over the next ten years.

Summary

• On February 24, 2025, Jerome Benedict Durso, a director of Altimmune, Inc., acquired 69,800 stock options.
• The options have an exercise price of $6.11.
• The options vest in 36 equal monthly installments starting from February 24, 2025, contingent upon continued service.
• The options expire on February 24, 2035.
• Following the transaction, Durso directly owns 69,800 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The stock options vest over a three-year period, incentivizing the director to remain with the company and contribute to its success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's increased stake in the company, which is common in the biopharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• The vesting schedule of 36 months is fairly standard.
• Comparing the size of the grant to similar companies would require more data on Altimmune's compensation practices and market capitalization.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates